Healthcare policy & drug development (The Cambridge Judge Business Debate podcast series)
How ageing societies can afford healthcare for all and reform an organisational system that has not kept pace with technology. L-R: Paul Tracey, Michael Kitson, Kamal Munir, Stefan Scholtes, Nektarios Oraiopoulos In this episode, joining podcast host Michael Kitson, University…
Manufacturing Chemist: Limits of drug repurposing
New research co-authored at Cambridge Judge Business School looks at drug repurposing and found that it’s not easy to find entirely new uses for existing molecules. The study is based on US Food and Drug Administration approvals and the full…
Limits of drug repurposing
Drug 'repurposing' has some high-profile wins, but a new study at Cambridge Judge Business School shows how hard it is to find entirely new uses for existing molecules. The "repurposing" of existing drugs can be valuable, but a new study…
New funding for Healx
Healx, a rare-disease company supported by the Entrepreneurship Centre at Cambridge Judge Business School, announces a $10 million Series A funding round led by Balderton Capital. Healx, a Cambridge-based company that seeks breakthroughs for rare diseases through artificial intelligence, announced…
Forbes: Healx raises $10m in funding to find medicines for rare diseases
Healx, a Cambridge-based company that seeks breakthroughs for rare diseases through artificial intelligence, announced a $10 million Series A funding round. Healx is supported by the Accelerate Cambridge programme at the Entrepreneurship Centre of Cambridge Judge Business School. The funding…
A framework for drug development
'Science is not enough' for ensuring commercial success of new drugs, so a new journal article co-authored by Dr Nektarios (Aris) Oraiopoulos of Cambridge Judge outlines a framework to help pharma companies align better with end-customer priorities. In most industries,…
